457 related articles for article (PubMed ID: 23375981)
1. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
Jang W; Park YJ; Park KG; Yu J
J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of extended-spectrum beta-lactamases and its correlation with clinical laboratory standards institute interpretive criteria for disk diffusion susceptibility testing in enterobacteriaceae isolates in Thaialnd.
Tangkoskul T; Tiengrim S; Onsomang S; Pati N; Aswapokee N; Thamlikitkul V; Chayakulkeeree M
Southeast Asian J Trop Med Public Health; 2012 Nov; 43(6):1461-9. PubMed ID: 23413710
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
5. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
Muro S; Garza-González E; Camacho-Ortiz A; González GM; Llaca-Díaz JM; Bosques F; Rositas F
Chemotherapy; 2012; 58(3):217-24. PubMed ID: 22814216
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
9. Molecular characteristics of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae from the Philippines.
Kanamori H; Navarro RB; Yano H; Sombrero LT; Capeding MR; Lupisan SP; Olveda RM; Arai K; Kunishima H; Hirakata Y; Kaku M
Acta Trop; 2011; 120(1-2):140-5. PubMed ID: 21820398
[TBL] [Abstract][Full Text] [Related]
10. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan.
Chia JH; Chu C; Su LH; Chiu CH; Kuo AJ; Sun CF; Wu TL
J Clin Microbiol; 2005 Sep; 43(9):4486-91. PubMed ID: 16145096
[TBL] [Abstract][Full Text] [Related]
11. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
12. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals.
Ko KS; Lee MY; Song JH; Lee H; Jung DS; Jung SI; Kim SW; Chang HH; Yeom JS; Kim YS; Ki HK; Chung DR; Kwon KT; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2008 Aug; 61(4):453-9. PubMed ID: 18482815
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of extended-spectrum beta-lactamases in Enterobacter cloacae in Taiwan and comparison of 3 phenotypic confirmatory methods for detecting extended-spectrum beta-lactamase production.
Yang JL; Wang JT; Lauderdale TL; Chang SC
J Microbiol Immunol Infect; 2009 Aug; 42(4):310-6. PubMed ID: 19949754
[TBL] [Abstract][Full Text] [Related]
16. Screening extended-spectrum beta-lactamase production in Enterobacter cloacae and Serratia marcescens using antibiogram-based methods.
Su PA; Wu LT; Cheng KC; Ko WC; Chuang YC; Yu WL
J Microbiol Immunol Infect; 2010 Feb; 43(1):26-34. PubMed ID: 20434120
[TBL] [Abstract][Full Text] [Related]
17. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
19. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods.
Steward CD; Rasheed JK; Hubert SK; Biddle JW; Raney PM; Anderson GJ; Williams PP; Brittain KL; Oliver A; McGowan JE; Tenover FC
J Clin Microbiol; 2001 Aug; 39(8):2864-72. PubMed ID: 11474005
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence of extended-spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae from Daejeon].
Ko CS; Sung JY; Koo SH; Kwon GC; Shin SY; Park JW
Korean J Lab Med; 2007 Oct; 27(5):344-50. PubMed ID: 18094599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
